Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lein

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
International Journal of Cancer|July 15, 2004
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implicationsKlaus Jung, Michael Lein, Carsten Stephan, et al.
The Prostate|January 15, 2009
Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acidMichael Lein, Kurt Miller, Manfred Wirth, et al.
The Prostate|January 9, 2003
Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) ratsKlaus Jung, Hans-Willi Krell, Bernhard Ortel, et al.
European Urology|May 16, 2006
A (-5, -7) proPSA based artificial neural network to detect prostate cancerCarsten Stephan, Hellmuth-Alexander Meyer, Maciej Kwiatkowski, et al.
Urology|August 11, 2007
Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populationsCarsten Stephan, Chuanliang Xu, Patrik Finne, et al.
The Prostate|January 5, 2002
Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell linesJu Zhang, Klaus Jung, Michael Lein, et al.
The International Journal of Biological Markers|July 28, 2009
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centersCarsten Stephan, Chris Bangma, Giulio Vignati, et al.
The Journal of Urology|October 23, 2012
Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosisJonas Busch, Kristin Hamborg, Hellmuth-Alexander Meyer, et al.
Clinical Chemistry and Laboratory Medicine|October 8, 2008
Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standardsCarsten Stephan, Anna-Maria Kahrs, Silke Klotzek, et al.
Clinical Chemistry|March 2, 2005
Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigenThomas Keller, Hermann Butz, Michael Lein, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
International Journal of Cancer|July 15, 2004
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implicationsKlaus Jung, Michael Lein, Carsten Stephan, et al.
The Prostate|January 15, 2009
Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acidMichael Lein, Kurt Miller, Manfred Wirth, et al.
The Prostate|January 9, 2003
Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) ratsKlaus Jung, Hans-Willi Krell, Bernhard Ortel, et al.
European Urology|May 16, 2006
A (-5, -7) proPSA based artificial neural network to detect prostate cancerCarsten Stephan, Hellmuth-Alexander Meyer, Maciej Kwiatkowski, et al.
Urology|August 11, 2007
Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populationsCarsten Stephan, Chuanliang Xu, Patrik Finne, et al.
The Prostate|January 5, 2002
Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell linesJu Zhang, Klaus Jung, Michael Lein, et al.
The International Journal of Biological Markers|July 28, 2009
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centersCarsten Stephan, Chris Bangma, Giulio Vignati, et al.
The Journal of Urology|October 23, 2012
Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosisJonas Busch, Kristin Hamborg, Hellmuth-Alexander Meyer, et al.
Clinical Chemistry and Laboratory Medicine|October 8, 2008
Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standardsCarsten Stephan, Anna-Maria Kahrs, Silke Klotzek, et al.
Clinical Chemistry|March 2, 2005
Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigenThomas Keller, Hermann Butz, Michael Lein, et al.
Pageof 11